Summary: Two vitamin projects of Shaoxing Jingxin passed EP acceptance inspection.
On 27 Dec., 2023, the passing results of post-completion environmental protection (EP) acceptance inspection on vitamin D3 project of Shaoxing Jingxin Pharmaceutical Co., Ltd. (Shaoxing Jingxin) were published, with a publication period ending on 24 Jan., 2024.
Overview of vitamin D3 project
Investment amount: USD7.16 million (RMB50.65 million); of which USD381,518 (RMB2.70 million) were for EP purposes
Type of project: technical renovation
Construction site location: Hangzhou Bay Economic and Technological Development Zone, Shangyu District, Shaoxing City, Zhejiang Province
Construction details: The project was carried out on the idle land of the company's factory compound. A standardised factory building was built. New production devices, including a reaction kettle, a condenser and a centrifuge, were purchased and installed. As for warehousing and shipping facilities, utilities and EP facilities needed by the project in daily operation, the existing ones have met the needs.
Production capacity: 60 t/a for vitamin D3 (including 58 t/a for oily VD3 and 2 t/a for crystalline VD3)
Timeline of developments in this project: The environment impact (EI) report was approved in Aug., 2022. Project construction commenced in Sept. 2022. On 31 May, 2023, the construction of main sections and supporting EP facilities were completed. Equipment commissioning was conducted on 1 June, 2023. On-site EP acceptance inspection was done in Oct. 2023.
On 21 Dec., 2023, the passing results of post-completion EP acceptance inspection on Shaoxing Jingxin's "construction project for enzyme liquid and calcifediol" were published, with a publication period ending on 19 Jan., 2024.
Overview of "construction project for enzyme liquid and calcifediol"
Investment amount: USD2.83 million (RMB20.00 million), of which USD154,020 (RMB1.09 million) were for EP purposes
Type of project: technical renovation
Construction site location: Hangzhou Bay Economic and Technological Development Zone, Shangyu District, Shaoxing City, Zhejiang Province
Construction details: The project was carried out in an existing workshop in the company's factory compound. New production devices, including a fermenter, a reaction kettle, a filter, a condenser, etc., were purchased and installed. As for warehousing and shipping facilities, utilities and EP facilities needed by the project in daily operation, the existing ones have met the needs.
Production capacity:
424 t/a for biological enzyme series products (amino acid deaminase liquid, etc.)
180 kg/a for calcifediol
Timeline of developments in this project: EI report was approved in Dec. 2021. Project construction started in Dec. 2022. In June 2023, the construction of main sections and supporting EP facilities was completed, and equipment commissioning was launched. On-site EP acceptance inspections were conducted twice, in July and Nov. 2023 respectively.
Wholly owned by a Shenzhen bourse-listed company Zhejiang Jingxin Pharmaceutical Co., Ltd. (Jingxin Pharma), Shaoxing Jingxin operates an important active pharmaceutical ingredient production base for its parent. Shaoxing Jingxin's products include pramipexole, levetiracetam, ciprofloxacin hydrochloride, etc.
There were several proposed or completed projects in 2023 that involve new production capacities for vitamin D3 and calciferol-related products. Information about these projects, compiled by CCM, is detailed as follows:
Sichuan Nansong Pharmaceutical Technology Co., Ltd.'s biopharmaceutical manufacturing base project
Location: Yuechi Economic and Technological Development Zone, Yuechi County, Guang'an City, Sichuan Province
Designed production capacities: 50 t/a for feed-grade VD3 and 10 t/a for food-grade VD3
Jiangxi Nuowei Biotechnology Co., Ltd.'s "reconstruction and expansion project for lanolin comprehensive utilisation project"
Location: Salt Chemical Industrial "City" (Park), Xingan County, Jiangxi Province
Designed production capacities: 60 t/a for oily VD3, 1,000 t/a for powdery VD3 and 10 t/a for crystalline VD3
Shandong Guoke Biopharmaceutical Co., Ltd.'s "R&D and production project for calcifediol and calcitriol"
Location: Biopharmaceutical Sci-tech Industrial Park, Rizhao Economic and Technological Development Zone, Rizhao City, Shandong Province
Designed production capacities: 1,601 kg/a for calcifediol and 1.1 kg/a for calcitriol
Phase II of Anhui Haoyuan Pharmaceutical Co., Ltd.'s "121.095 t/a pharmaceutical raw materials and intermediates construction project"
Location: Ma'anshan Cihu High-tech Industrial Development Zone, Anhui Province
Designed production capacities: 10 kg/a for alfacalcidol, 2 kg/a for eldecalcitol, 3 kg/a for calcitriol and 80 kg/a for calcipotriol
Source:CCM
More information can be found at CCM Vitamins China Monthly Report.
About CCM:
CCM
is the leading market intelligence provider for China’s agriculture,
chemicals, food & feed and life science markets. Founded in 2001,
CCM offers a range of content solutions, from price and trade analysis
to industry newsletters and customized market research reports. CCM is a
brand of Kcomber Inc.
For
more information about CCM, please visit www.cnchemicals.com or get in
touch with us directly by emailing econtact@cnchemicals.com or calling
+86-20-37616606.